Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyGlobeNewsWire • 01/27/23
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.GlobeNewsWire • 11/23/22
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of DirectorsGlobeNewsWire • 09/07/22
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet SyndromeGlobeNewsWire • 08/31/22
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development OrganizationGlobeNewsWire • 06/27/22
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet SyndromeGlobeNewsWire • 05/12/22